| Amrubicin | 15 | ? | 3 (1 - 14) |
| Platinum + etoposide | 14 | ? | 2 (1 - 16) |
| Irinotecan | 8 | ? | 1.5 (1 - 13) |
| Nogitecan | 6 | ? | 1.5 (1 - 4) |
| Other drugs | 3 | ? | 2 (1 - 3) |
| NSCLC regimens |
|
|
|
| Docetaxel | 17 | ? | 2 (1 - 59) |
| Pemetrexed | 15 | ? | 3 (1 - 23) |
| Platinum + third − generation drugs | 10 | ? | 3 (1 - 6) |
| Platinum doublet + bevacizumab | 10 | ? | 3.5 (1 - 7) |
| Pemetrexed + bevacizumab | 9 | ? | 6 (1 - 15) |
| Bevacizumab | 8 | ? | 4 (2 - 16) |
| Gemcitabine | 7 | ? | 3 (1 - 9) |
| Vinorelbine | 7 | ? | 3 (1 - 10) |
| Irinotecan | 6 | ? | 3.5 (1 - 21) |
| Platinum + pemetrexed | 5 | ? | 1 (1 - 5) |
| Other drugs | 9 | ? | 3 (1 - 19) |